George Washington University has collaborated with Moderna to test the safety of the first mRNA HIV vaccines and the immune responses of two participants in the Phase 1 clinical trial. Four institutions, including GW, have enrolled 56 HIV-negative adult participants for the vaccines’ clinical trials. The mRNA HIV vaccine aims to block the replication of HIV strains and stimulate the production of broadly neutralizing antibodies that control the virus within HIV-positive patients’ immune systems. Read more by clicking the link!
University administers first doses of mRNA HIV vaccine through Moderna partnership
Latest News
The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were…
VRU Director, Dr. David Diemert, attends the annual Joint Coordinating Board meeting of TDR (Special Programme for Research and Training in Tropical Diseases) of the WHO in Geneva, Switzerland